Alexandra Sowa, MD

Alexandra Sowa, MD operates a telehealth-based metabolic health practice in New York, NY, specializing in physician-supervised weight loss through GLP-1 receptor agonist peptide therapy. Dr. Sowa's clinical model centers on evidence-based pharmacotherapy combined with structured nutritional guidance and hydration protocols, designed for patients seeking medical intervention for obesity and metabolic dysfunction. The practice serves patients across New York State through secure virtual consultations, eliminating geographic barriers while maintaining rigorous medical oversight.

The clinic's peptide therapy program features three FDA-approved GLP-1 medications: liraglutide, semaglutide, and tirzepatide. Liraglutide is typically prescribed as a daily subcutaneous injection for patients requiring gradual appetite suppression and glycemic control. Semaglutide, administered weekly, offers enhanced weight reduction outcomes and is often selected for patients with higher baseline BMI or those who have plateaued on other interventions. Tirzepatide represents the practice's dual-agonist option, targeting both GLP-1 and GIP receptors for patients requiring maximum metabolic impact or those with concurrent type 2 diabetes. Dr. Sowa individualizes peptide selection based on patient metabolic profile, weight loss goals, insurance coverage, and tolerance to gastrointestinal side effects common with this medication class.

Dr. Alexandra Sowa brings board certification in internal medicine to her weight management practice, with clinical training that emphasizes the physiological mechanisms underlying obesity as a chronic disease rather than a lifestyle failure. Her treatment philosophy integrates peptide pharmacotherapy with evidence-based nutritional counseling, recognizing that GLP-1 medications alter hunger signaling and satiety but require concurrent dietary modification for optimal outcomes. The practice emphasizes adequate hydration as a cornerstone of peptide therapy success, addressing the increased risk of dehydration and constipation that can occur with reduced food intake and slowed gastric emptying. Patients receive specific hydration targets and electrolyte guidance tailored to their peptide regimen and weight loss phase.

Patients initiating care with Dr. Sowa undergo comprehensive telehealth evaluation including metabolic history, prior weight loss attempts, current medications, and contraindication screening for GLP-1 therapy. Initial consultations establish baseline weight, BMI, and metabolic parameters, followed by peptide selection and dose titration planning. The practice employs gradual dose escalation protocols to minimize nausea, vomiting, and other gastrointestinal side effects while achieving therapeutic effect. Follow-up visits occur at regular intervals to assess weight trajectory, adjust dosing, monitor for adverse effects, and reinforce nutritional strategies. Dr. Sowa's approach acknowledges that peptide therapy requires ongoing medical supervision, with particular attention to gallbladder function, pancreatic health, and thyroid monitoring based on emerging safety data for long-term GLP-1 use.

The telehealth delivery model offers distinct advantages for weight management patients in New York, NY, including flexible scheduling, privacy for sensitive health discussions, and continuity of care without transportation barriers. Dr. Sowa's practice coordinates prescription fulfillment through specialty pharmacies experienced in handling temperature-sensitive peptide medications and provides patients with injection technique training via video consultation. The virtual care framework allows for responsive communication during dose adjustments or side effect management, critical periods when patients may require guidance between scheduled visits. This accessibility, combined with Dr. Sowa's focused expertise in GLP-1 pharmacotherapy and metabolic medicine, positions the practice as a specialized resource for New York patients seeking medical weight loss beyond conventional diet and exercise approaches.